Key takeaways
- GHK-Cu is a copper complex; KPV is the Lys-Pro-Val sequence.
- A small randomized human study of GHK-Cu had 13 completers in 2006; KPV research cited here is in cells and mice.
- FDA staff proposed not adding KPV to the 503A bulks list (July 2026); HHS records that its advisory committee voted in favour, and HHS’s October 2026 draft policy, which “is not binding”, names KPV.
- Neither name appears on WADA’s 2026 or 2027 List; WADA says a peptide not specifically named “may still be prohibited”.
01GHK-Cu vs KPV in one table
A side-by-side summary. Regulatory records were checked for this draft on 21 November 2026; unresolved points are labelled.
| Question | GHK-Cu | KPV |
|---|---|---|
| Identity | Copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine (GHK) | Tripeptide Lys-Pro-Val, also known as α-MSH(11–13) |
| Evidence tiers in studies cited here | One small randomised human skin study (T1); GHK-Cu’s animal (T3) and cell (T4) studies are on its guide | Human cell studies (T4) and animal models (T3); these are not evidence of an effect in people |
| Human data | Miller et al. (2006): randomised study; 13 participants completed. Among the measures: erythema and evaluator ratings of skin appearance. Material sold online is not the formulation tested. | FDA reported no identified clinical studies or human exposure data for KPV in its July 2026 briefing. |
| United States | FDA’s list of substances nominated for compounding (updated 14 May 2026) places GHK-Cu, for certain routes of administration only, in Category 1, bulk drug substances under evaluation; it is not in HHS’s October 2026 draft policy. The FDA records, dated: GHK-Cu research guide. | FDA staff proposed not adding KPV to the 503A bulks list (July 2026 briefing); HHS records that the advisory committee voted in favour. HHS’s October 2026 draft policy, which “is not binding”, names KPV. |
| United Kingdom | The emc medicines database returned no results for GHK, copper tripeptide or prezatide (21 Nov 2026); it is not the full UK register | The emc database returned no results for KPV (21 Nov 2026) |
| Australia | The TGA says that “many products promoted online are unapproved therapeutic goods and may be unlawful to import, supply or advertise. Using unapproved peptide products can pose serious health risks.” GHK-Cu has no entry by name in the Poisons Standard October 2026, which has group entries for copper compounds; we draw no scheduling conclusion of our own. | For KPV, the TGA statement on the left; KPV has no entry by name in the Poisons Standard October 2026, and we draw no scheduling conclusion of our own. |
| WADA, 2026 and 2027 Lists | Not named. WADA says a peptide not specifically named “may still be prohibited” | Not named, as on the left |
02How are GHK-Cu and KPV different in identity?
If you searched “kpv vs ghk cu,” the first distinction is chemical identity. Both names refer to three-amino-acid peptides, but GHK-Cu also includes copper(II). KPV is the Lys-Pro-Val sequence at the C-terminal end of α-MSH; it is not a copper complex.
GHK-Cu
Three amino acids complexed with copper(II). The sequence is glycyl-L-histidyl-L-lysine.
KPV
Three amino acids in the order Lys-Pro-Val; it is also called α-MSH(11–13).
Names alone do not establish what a particular sample contains. To assess an identity result, see how to read a COA.
03What models have researchers studied?
These are study designs, not evidence that either peptide has an effect in people. T3 means animal evidence; T4 means cell or mechanistic evidence.
| Peptide and study | Model | What researchers measured | Evidence tier |
|---|---|---|---|
| KPV, Dalmasso et al. (2008) | Human intestinal epithelial cell lines, a human T-cell line, and two mouse models | Cell signalling, cytokine measures, and tissue histology | T4 and T3; not evidence of an effect in people |
| KPV, Elliott et al. (2004) | Human keratinocyte cells | Intracellular signalling responses | T4; not evidence of an effect in people |
| GHK-Cu, Miller et al. (2006) | Randomized human study; 13 participants completed | Erythema and evaluator ratings of wrinkles and skin appearance | T1, small; material sold online is not the formulation tested |
The models and measures differ. They do not create a direct comparison between GHK-Cu and KPV, and results from one peptide cannot be assigned to the other.
04What does the human evidence show?
For KPV, FDA’s July 2026 briefing says the agency had not identified clinical studies or human exposure data. That is a dated search finding, not proof that no such data could ever exist. The cell and mouse papers cited above do not answer how KPV behaves in people.
For GHK-Cu, Miller and colleagues published a small randomized human study in 2006. Thirteen participants completed it. The study recorded erythema and evaluator ratings after a skin-resurfacing procedure. Those design details say what was studied, not whether GHK-Cu had an effect, and material sold online is not the formulation tested.
For a closer look at the GHK-Cu record and its limits, read the GHK-Cu research guide. The evidence grades page explains how we label study types.
05What do the regulatory records not settle?
The country rows in the table describe specific documents, not a single worldwide legal status. For the United States, FDA staff’s KPV recommendation concerns a compounding list. It does not by itself resolve every product or legal question. In the UK, the emc medicines database returned no results for either name (21 November 2026); it is not the full UK register.
In Australia, the October 2026 Poisons Standard does not name GHK-Cu or KPV. It has group entries for copper compounds, but this page does not decide whether those entries apply to GHK-Cu. We draw no scheduling conclusion from the name searches.
Neither GHK-Cu nor KPV is named in WADA’s 2026 List. The List also has broader classes: an unnamed substance may still fall within a class. Absence by name is not a conclusion that either peptide is permitted in sport.
- We do not know whether results from cell or animal models predict an effect in people.
- FDA reported no identified human exposure data for KPV in its July 2026 briefing; its human safety profile remains unknown in that document.
- This comparison does not determine the status of a specific finished product in the United States, United Kingdom or Australia.
- A study of one peptide does not establish a result for the other.
This is a plain-English summary of public studies and documents, checked on 21 November 2026. It is not legal or medical advice.